Search results for AN-170

HSD3B7 (aa121-170) antibody, Covalab, Ref 00107621

MRPL13 (aa121-170) antibody, Covalab, Ref 00107622

AGPAT3 (aa121-170) antibody, Covalab, Ref 00110979

SNX2 (aa120-170) antibody, Covalab, Ref 00023511

CD11b antibody (MEM-170), Covalab, Ref 00113195

Centrosomal Protein 170 (CEP170) Antibody, Abbexa, abx249449

CEP170 Antibody is a Rabbit Polyclonal against CEP170.

Anti-ABCA7 antibody [EPR28772-170], Abcam, AB323799

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

Centrosomal Protein 170 (CEP170) Antibody, Abbexa, abx324643

CEP170 Antibody is a Rabbit Polyclonal against CEP170.

Anti-E2F2 antibody [EPR27391-170], Abcam, AB318956

Patented technology Our RabMAb ® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb ® patents . What are the advantages of a recombinant monoclonal antibody? This product is a recombinant monoclonal antibody, which offers several advantages including: - High batch-to-batch consistency and reproducibility - Improved sensitivity and specificity - Long-term security of supply - Animal-free batch production For more information, read more on recombinant antibodies .

TNF-RI, Mouse, mAb 55R-170, Hycult Biotech, HM1097

TNF-RI belongs to the large TNF receptor family, among which TNF-RII (TNF-R p75-80), lymphotoxin-beta receptor (LTbetaR) and the Herpes virus entry mediator (HVEM). Ligands for these receptors belong to the Tumor Necrosis Factor (TNF) superfamily of cytokines, which activate signaling pathways for cell survival, death, and differentiation that orchestrate the development, organization and homeostasis of lymphoid, mammary, neuronal and ectodermal tissues. TNF-RI contains a characteristic structural cassette termed death domain in its sequence that is conserved within a distinct subset of other TNF-R family members, such as CD95, DR3, DR4, and DR5. This death domain, was characterized as being essential for induction of apoptosis in vitro and has been structurally conserved within these TNF-R superfamily members. Deletion of the death domain of the TNF-RI results in a non-functional receptor, indicating that the death domain is required for the signal transduction of the physiological functions of TNF-RI in vivo. TNF-RI is a 55 kD type I transmembrane protein and is expressed on a variety of cell types at low levels. It is considered to play a prominent role in cell stimulation by TNF-alpha. Induction of cytotoxicity and other functions are mediated largely via TNF-RI. TNF-RI is present as soluble form in body fluids (for instance plasma and CSF). This extracellular TNF-RI is generated by two mechanisms, namely proteolytic cleavage of TNF-RI ectodomains and release of full-length TNF-RI in the membranes of exosome-like vesicles. TNF-RI and TNF-RII both interact with the homomeric forms of LTbeta or TNF. However, TNF-RI functions as the high affinity receptor for soluble TNF (sTNF). TNF-RI has been shown to be involved in a wide variety of inflammatory diseases, among which neurodegenerative diseases (Parkinson’s and Alzheimer’s disease), multiple sclerosis, asthma, atherosclerosis, rheumatology. The monoclonal antibody 55R-170 also recognizes the soluble receptor..